



human CAP-1

MLSHNTMMKQRKQQATAIMKEVHNDVGMDLGKKVSI PRDIMLEELSHLSNRGARLFKM
60
QRSSDKYTFENFQYQSRQINHSTAMQNGKVDGSNLEGGSQQAPILTPPNTDPRSPPNP
120
DNTIAPGYSGPLKEIPPEKFNTTAVPKYYQSPWEQAIISNDPELLEALYPLKFKPEGKAELP
180
DYSRFSNRVATPFGGERASRMVKFVDPDELLLTDPRFMSFVNPLSGRRSFNRTPKGWT
240
SENIPVITTEPTDDTIVPESEDL

FIG. 1A

mouse CAP-1

MLSHSAMVKQRKQQASSAITKEIIGHDVGDGMDLGKKVSI PRDIMIEELSHFSSNRGARLFKM
60
QRSSDKYTFENFQYESRAQINHNTAMQNGRVDGSNLEGGSQQGPSTPPNTDPRSPPNP
120
ENIAPGYSGPLKEIPPERFNTTAVPKYYRSPWEQAIIGSDPELLEALYPLKFKPEGKAELR
180
DYSRFSNRVATPFGGEKASKMVKFVDPDELLLTDPRFILAFANPLSGRRCFNRAPKGWT
240
SENIPVITTEPTEDATVPESDL

FIG. 1B

human CAP-2

MPLSGTPAPNKKRKSSKLI
MELTGGRESSGLNLGKKISVPRDVM
LEELSLTNRGSKMF
60
KLRQMRVEKFIYENHPDVFSDSSMDHFQKFLPTVGGQLGTAGQFSYS
KSNSGRGGSQAGG
120
SGSAGQYGS
DQQEHHLGS
GAGGTGGPAGQAG
RGGAACTAGVGET
GSGDQAG
GECKHITV
180
EKTYYIS
WERAMGV
DQQK
MELG
GIDLLAY
GAKAEL
LPKYK
SFNRTAMP
YGGYE
KASKR
MTF
240
QMPKFDL
GPLLSEPL
VLYNQNL
SNRPSF
NRTPI
PWLS
SSGE
PVDN
VDF
GIP
LDGET
EEL

FIG. 1C

mouse CAP-2

MPLSGTPAPNKR
RKSSKLI
MELTGGRESS
GLNLGK
KISVPRDVM
LEELSLTNRGSKMF
60
KLRQMRVEKFIYENHPDVFSDSSMDHFQKFLPTVGG
QLETAGQ
GFSYS
GKSSGG
QAGSSG
120
SAGQYGS
DRHQ
GSGFG
AGGSG
GGQAG
GGCAP
GTVGL
GEP
GSGD
QAG
GDGK
HVT
VFKT
180
YIS
SPW
DRA
MGV
DQQ
KVEL
GID
LLAY
GAK
AEL
LPKY
KSF
NRT
AMP
YGG
YE
KASK
RMT
FQMP
240
KFDL
GPLL
SEPL
VLYNQNL
SNRPSF
NRTPI
PWLS
SSGE
PVDN
VDF
GIP
LDGET
EEL

FIG. 1D

FIG. 1E

human CAP-1

10 20 30 40 50 60 70 80 90 100
 GTCCCAGGTTCAAGGATAAAAACCATCAGGCCAAGTCCATCCTAGTCATCTCAGAGTCTCTCACA
 CAGGGTCCAGTTCTATTTGGTAGCTCGGGTTCACGGTAGTCACTGGAGGTCTCAGAAGGAGGTT
 110 120 130 140 150 160 170 180 190 200
 CACAACTCAACAGCAAGGACAAAACCATGCTATCACATAATCTAGTGAAGCAGAAAACAGCA
 CAGGAAACTCATGCTGGTACGGTACGGTAGTCTCTGAGTACACCCCTTAAATAGGGTAGTC
 GTGTTAGATGTTGTTCTCTTGTGTTGGTAGATGTTATGATACTCTCTCTCTGTTGTTG
 210 220 230 240 250 260 270 280 290 300
 GGAATGATGTTGATGGCATGGCCCTGGGAAAGGTCAGCATCCCTAGAGACATCTAGTGG
 CTTTACTACAACTACCGTACCTGGACCCGTTTCCAGTCAGGGTCTCTGAGTACACCC
 310 320 330 340 350 360 370 380 390 400
 TATTTAGATGCGTAAAGGATCTCAAACTACATTGAAATTCTCTAGATCTACAGC
 ATAAATTCAGCAGTTCTAGACTGTTATGTTAACTTAAAGGTCTAGTTAGATCTGTT
 410 420 430 440 450 460 470 480 490 500
 GAAAGTGGATGGAAGTAACTGGAGGTTGGCAGCAAGGCCCTGACTCTCCCA
 CTTTACCTCTTCAATTGAACTTCCACCCANGCTCGTCCGGGAACTCTGGGGTCTAG
 510 520 530 540 550 560 570 580 590 600
 GCTCCAGGATATTCTGGACACTGGAAGAAATCTCTCTGAAATTCA
 CGAGGTCTTAAAGACCTGGTACTCTTAAAGGAGGACTTTAGTTGTTGTC
 610 620 630 640 650 660 670 680 690 700
 GCAATGATCCGGAGCTTAAAGGCTTATATCTAACTTCTCAGGGTCAAGGG
 CGTTACTAGGCTCGAAATCTCGAAATATAGGATTGAAAGTTGCGACT
 710 720 730 740 750 760 770 780 790 800
 ACCATTGGAGGTTTAAAGCATCAAGATGGTAAATTAAAGTTGCT
 TGGTAAACCTCAAACATTTCGTTAGTCTTACCAATTAACTTCAG
 810 820 830 840 850 860 870 880 890 900
 ATCCCCCTTCTGGCAGCGCTTTAAAGGACTCTA
 TTAGGGAAACCGCTGCAGGAAATTCTCTAGGATCTACCTATAG
 910 920 930 940 950 960 970 980 990 1000
 CTGTAACGAACTCAGAAAGCTTATGAAAGTTGCTATG
 GACATGGTCTTAGTCTCTGAGTACCTTCTTACACAG
 1010 1020 1030 1040 1050 1060 1070 1080 1090 1100
 CACTGGCATTTCATAGTCAACAAATAGTCA
 GTGAACTTAAAGTAATCTGTTGTTAGTCA
 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
 ATCTTACCTAAACCTTAAACTCACTTCTCTCAT
 TAGAATGAAATTCTGAGTCAACAGAAGTA
 1210 1220 1230 1240 1250 1260 1270 1280 1290 1300
 AAAAGTAATGACAGCTCCTTCTCATTTATGTT
 TTTTCAATTACTGTCGAAGTGGAAACAG
 1310 1320 1330 1340 1350 1360 1370 1380 1390 1400
 AAGACCTTCAAGGTTCTGGGATGAAGCT
 TTCTGGATAACTCTGAGGACCCCTACTTCT
 1410 1420 1430 1440 1450 1460 1470 1480 1490 1500
 TGAGAAATAATGTCCTGAGTCTTCTTCT
 ACTCTTTATATACAGAACTCTCAGAA
 1510 1520 1530 1540 1550 1560 1570 1580 1590 1600
 ATCTGGATGATATCTCAAATTCTCAGT
 1610 1620 1630 1640 1650 1660 1670 1680 1690 1700
 GTTTAAAGGACCAAGGTGTCGGCAGAATT
 CAAATTCTCTGTTCCACAGGGCTTAAAG
 1710 1720 1730 1740 1750 1760 1770 1780 1790 1800
 AACAAATAAGTACACGTTAACTATAC
 TTTGTTTCTCTGAGTCA
 1810 1820 1830 1840 1850 1860 1870 1880 1890 1900
 TTAATCTCTTAAAGATCTCAAGTA
 ATTAAAGGAGTACATCTTCT
 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000
 TCTATGCTTATATATATATATATATAT
 AGATGCTTATATATATATATATATAT
 2010 2020 2030 2040 2050 2060 2070 2080 2090 2100
 CTATAGAAATCTAGTCACTTCTCC
 2110 2120 2130 2140 2150 2160 2170 2180 2190 2200
 ATCGATAAAGTTTCTAGGAGATAGGA
 2210 2220 2230 2240 2250 2260 2270 2280 2290 2300
 CTGCAAGTTGACTTTAACTCAGTCA
 CACCTTCAACCACTGACAA
 2310 2320 2330 2340 2350 2360 2370 2380 2390 2400
 CAAAGTATTAATGTTATATATAT
 GTGAGAATTGTTATATATAT
 2410 2420 2430 2440 2450 2460 2470 2480 2490 2500
 TTTAAATGATAATCTGCACTG
 ATAAATTTTACTTAAACCCG
 2510 2520 2530
 ATAAATTTTCTTAAACCCG

FIG. 2A

mouse CAP-1

10 20 30 40 50 60 70 80 90 100
ATTCGGCAGATGGGATCGAGGGACCATGGCGTTCCAGGTCAGGATAAAAACCCATGGGCATAGTGCGCTATATTCACCTTCAGTGCCCTCCCA
TAAGCCCTGTAACCCCTAGCTCCCTGGTAGGCCAAGGTCACCTTCATTTGGTACCCGATACGGCAGTATAAGGGAAAGTCACGGAAAGGAGGT
110 120 130 140 150 160 170 180 190 200
CAATTGGGATTCACCCCTGCTGAAAAGGCCACGGCTCACCCAGGGACACAAAACATATGCTATCACATAGTGCCATGGTGAACCAAGGAAACAGCAAC
GTAAACCTTAAGTGGGACGACTTTGGCTGCGACTGTGTCCCTGTGTTTTGATACGATAGTGATACGGTACCCACTTCGTTTCCTGCTTC
210 220 230 240 250 260 270 280 290 300
CATCAGCCATACGAAGGAAATCCATGGACATGATGTTGACGGCATGGACCTGGGCAAAAAGTTAGCCATCCCAGAGACATCATGATAGAAAGAATTGTC
GTAGTCGGTACTGCTTCCCTTAGGTACCTGACTACAACTCCGTACTGGACCCGTTTCAATGTAGGGTCTCTGTAGTACTATCTTAAACAG
310 320 330 340 350 360 370 380 390 400
CCATTTGAGTAATCGTGGGCCAGGGCTTTAACATGGCTAACAGAAGATCTGACAAATACACCTTGAAAATTTCAGTATGAACTTAGAGCACAAATT
GGTAAGACTCAATTAGCACCCCGGTCGACAAATTCAGCGATTTCTCTAGACTGTTAATGTGGAAACTTTAAAGGTCAACTTAGATCTCGTGTAA
410 420 430 440 450 460 470 480 490 500
AAATCACAAATGGCCATGCAAAATGGGAGACTTGATGGACCAACCTGGAAAGGTGGCTCACAGCAAGGCCCCCTCAACTTCGGCCAAACACCCCCGATCCAC
TTAGTCGTTATAGCGGTACGGTCTTACCCCTCTCAACTACCTTGTTGACCTTCACCGAGTGTGGTCTCGGGGAGTTGAGCCGGGTTGTGGGCTTAGGTG
510 520 530 540 550 560 570 580 590 600
GAAGCCCCAAATCCAGAAACATGGCACCAGGATTTCTGGACACTGGAAAGGAATTCTCTGAAAGGTAAACACGACGGCTCTCTAAGTACTA
CTTGGGGGGTTAGGTCTTGTAGCGTGGCTCTAAACACCTGGTCACTCTTAAAGGAGGACTTTCAATTGTGCTCCGGCAAGGATTCATGAT
610 620 630 640 650 660 670 680 690 700
CCGGTCCTCATGGGAGCAGGGCATGGCAGGATCGGAGCTCGGAGCTCTGGAGCTTGTACCCAAAACCTTTCAAGCCTGAAGGAAACACACAAACTGGGGAT
GGCCAGACGTACCCCTGTCGGCTAACCGTGGCTAGGCCCTGGAGGACCTGGAAACATGGGTTTGTGAAAGTTGGGACTCTTGTCTGACGCCCTA
710 720 730 740 750 760 770 780 790 800
TACAGGAGCTTAAACGGGTGGCACTCCATTTGGAGGTTTGAAAAGCATCAAAATGGCTAAATCAAGGTCAACTTGGTCAACTACTGCTGCTGA
ATGCTCTGAAATTGCTCCAACGGTGGTAACCTCCTCAAAACTTTTGATGTTTACCAAGTAAAGTTCAAGGTCTAAACTTGATGACGACGACT
810 820 830 840 850 860 870 880 890 900
CACATCCCAGGTTTGGCTTGGCAATCTCTTGGGGCAACGGATGTTAACAGGGGCCAAAGGGGGGGTATCTGAGAAATATCCCCTGGTGT
GTCTAGGGTCAAGAACGGAAACGGTGGAGAAAGGCCGTTGGCTACGAAATTGCTCCGGGTTCCCAACCCATAGACTCTTATAGGGGCAAGCACT
910 920 930 940 950 960 970 980
CACAACTGAGCTACACAAGACGGCACTGTACCGGAATCAGATGACCTGTGAGAGGGAGCTGGGGATGCCACAGGAATTC
GTGTTGACTGGATGTTCTGGGTGACATGGCTTACTGACACTCTCCCTGGACCCCTACGGTGTCTTCAG
FIG. 2B

human CAP-2

CGCTCACACC AGCTCAGTCC TCCAAAGCTG CTGGACCCCC CGGAGAGCTG ACCACTCCCC GAGCAGCCCC CTCATTCAC CTCCACATG CGCTCTCAG
200
GAACCCGGC CCCTAATAANG AAGAGGAAT CCACCAAGCT GATCATGGAA CTCACCTGGAG CTGGACAGGA GAGCTCAGGC TTCAACCTGG GCAAAAAGAT
300
CACTGCTCCA AGGGATGTCA TGTTGGAGGA ACTCTGGTG CTTACCAACC GGGCTCCAA GATGTCAAA CTGGCCAGA TGAGGGTGG AAGTTTAT
400
TATGAGAACC ACCCTGATGT TTCTCTGAC AGCTCAATGG ATCACTTCCA GAAGTCCCTT CCACAGTGG GGGCACAGCT GGGCACAGCT CGTCAGGGAT
500
TCTCATACAG CAAGAGCAAC GGCAAGAGGGC GCAGCCAGGC AGGGGGCAGT CGCTCTGCCG GACAGTATGG CTCTGATCAG CAGCACCCATC TGGGCTCTGG
600
GCTCTGGAGCT GGGGTACAG GTGGTCCCCG GGGCCAGGCT GGCAAGAGGAG GACCTCTGG CACACAGGGG TTGGTGGAGA CAGGATCAGG AGACCAAGGCA
700
GGGGAGAGAG GAAACATAT CACTGTGTC AAGACCTATA TTTCCTCATG GGAGGGAGCC ATGGGGTTG ACCCCAGCA AAAATGGAA CTTGGCATTG
800
ACCTGCTGGC CTATGGGCC AAAGCTGAAC TTCCCAATA TAAGTCTTC AACAGGAGG CAATGCCCTA TGGTGGATAT GAGAAGGCCT CCAAACGGAT
900
GACCTCCAG ATGCCCAAGT TTGACCTGGG CCCCTTGCTG AGTGAACCCC TGTCCTCTA CAACCAAAAC CTCTCCAAAC GGCCTCTTT CAATCGAAC
1000
CCTATTCCCT GGCTGAGCTC TGGGGAGGCT GTAGACTACA ACGTGGATAT TGGCATCCCC TTGGATGGAG AAACAGAGGA CCTGTCAGGT TTTCCTCTT
CTGATTGCA TCATTTCCCC TCTCTGGCTC CAATTGGAG A

FIG. 2C

mouse CAP-2

CCCCGGAGA CCCACCAACC AACTGAGGAG CTGGTCAGAT CCACCTCCAC CATGCCACGC TCAAGGAACCC CGGCCCTAA CAAGACGGAGG AAGTCAGCA
100
AACTGATTAT GGAGCTCACT GGAGGTGGCC CGGAGAGCTC AGGCCTGAAC CTGGCAAGA AGATCAGTGT CCCAAGGGAT GTGATGTTGG AGGAGCTGTC
200
CTTCTTACCC AACCCAGGCT CCAGAGATTT CAAGCTACGG CAGATGGGG TGGAGAAATT TATCTATCG AATCACCCCCG ATCTTTCTC TGACACCTCA
300
ATGGATCACT TCCAGAAGTT TCTTCCCACA GTGGGAGGAC AGCTGGAGAC AGCTGGTCAG GGCTTCTCAT ATGGCAAGGG CAGCAGTGGA GGCCAGGCTG
400
GGAGCACTGG CTCCTCTGGG CAGTATGGCT CTGACCGTCA TCAGCAGGGC TCTGGGTTG GAGCTGGGGG TTCAAGGTGGT CCTGGGGGCC AGGCTGGTGG
500
AGGAGGAGCT CCTGGCACAG TAGGGCTTGG AGAGCCCCGA TCAGGTGACC AGGAGGTGG AGATGGAAA CATGTCAGT TGTTCAAGAC TTATATTC
600
CCATGGGATC GGGCCATGGG CGTTGATCCT CACCAAAAAG TGGAACCTGG CATTGACCTA CTGGCATAAG GTGCCAAAGC TGAACCCCC AAAATAAAGT
700
CCTTCACAG GACACCAATG CCCTACGGTG GATATGAGAA GGCTCCTAA CGCATGACCT TCCAGATGCC CAAGTTGAC CTGGGGCTC TGCTGAGTGA
800
ACCCCTGGTC CTCTACAAACC AGAACCTCTC CAACAGGCT TCTTCAATC CAACCCCTAT TCCCTGGTTG AGCTCTGGGG ACCATGTAGA CTACAACGG
900
GATGTTGGTA TCCCCCTGGG TGGAGAGACA GAGGAGCTGT GAAGTGGCTC CTCCCTGTCAT GTGCAATCATT TCCCTCTCT GTTTCCTATT TGAGAGTGG
1000
TGCTGGACAG GATGCCCAA CTGTTAATCC AGTATTCCTG TGGCAATGGG GGGTAAGGG TGGGGTCCGT TGCCTTTCCA CCCTTCAGT TCCCTGCTCG
1100
AAGCATECCT CCTCACCCAGC TCAGAGCTCC CATCCCTGCTG TACCATATGG AATCTGCTCT TTATGGAAT TTCT

FIG. 2D




FIG. 3

FIG. 4A




FIG. 4C




FIG. 4B



FIG. 4D




FIG. 4E

FIG. 5A




FIG. 5B

Fig. 5. Co-localization of calmodulin-1 and alpha-actinin in the rat heart. (A) Control heart. (B) Heart 1 h after 10% isovolemic hemorrhage. (C) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion. (D) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (E) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (F) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (G) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (H) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (I) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (J) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (K) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (L) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (M) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (N) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (O) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (P) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (Q) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (R) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (S) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (T) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (U) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (V) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (W) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (X) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (Y) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion. (Z) Heart 1 h after 10% isovolemic hemorrhage and 1 h after 10% retransfusion and 1 h after 10% retransfusion.

FIG. 6A




FIG. 6B





FIG. 6C






FIG. 7




FIG. 8

Calsarcin-3





FIG. 9




FIG. 10





FIG. 11

FIG. 12



ClustalW Formatted Alignments

calysarcin-3	1	M P . . . K E Q K Q P M A A Y G D D L T E P V P T I D L G R K Y S V P Q D M M E E I S L R N N R	47
calysarcin-2	1	N P L S C T P A P . . . K R N S S K T M E T G G Q E S S G L N I L G K K S V P R D M I L E I S L L N R	55
calysarcin-1	1	N L S H N T M K O R K O Q A M K E H G . . . N D V D G W D I L G R K S P R D M I L E I S L L N R	53
calysarcin-3	48	G S L L F Q K R Q R R V Q K F T F E L A A S Q R A M L A G S A R R K V Q P A B S G T V A N A N G Q P E O P N Y	102
calysarcin-2	56	G S L L F Q K R Q M R V E K F I Y E N H P D V . . . F S D S S M D F F Q N F E P V G G O Q O F S . . . Y S	108
calysarcin-1	54	G S L L F K R Q R R S D K T F E N . . . F Q Y Q S R A Q I N E S A M O N G K V D . . . G	94
calysarcin-3	103	S E L L I F P A S P G A S L Q Q P E G A H P A A P G V V E P I K N O V D P	152
calysarcin-2	109	S N Q S G G S Q Q G Q S D Q Q H H L G S G S G Q G T G P A Q C A G K Q O A A G	158
calysarcin-1	95	S N I E G G S Q Q . . . A P L P P N T P D P S P P N P D N S N D P E L L E A L Y P K L F K P E D P	136
calysarcin-3	153	· · · · · E R F N H T A S P K C Y E C P W Q E F V S Y R D Y Q S D G R S	183
calysarcin-2	159	R T Q V G E T G S Q D Q A G G E Q K H I V F K T Y I S P W E R A M G D P Q Q K M E L O I D L L A Y G A K A	213
calysarcin-1	137	· E R F N T T A V P K Y Y Q S P W E Q A S S N D P E L L E A L Y P K L F K P E G K A	177
calysarcin-3	184	H T P S P N D Y R N F N K T P P F G G P L V G G . . . T F P R P . . . G T P F I P E P L S C I E L P R L R	231
calysarcin-2	214	E L P . . . K Y S S F N R T A P P G G E K A S K R M T F O M K F D I G P H L S E P L L N Q N P L S G R	265
calysarcin-1	178	E L P . . . D Y R S F N R V A T P P G G E K A S K R M T F K V P D F E L L I T D P R F M S F V N P L S G R	229
calysarcin-3	222	P S F N R V A Q G W R N L P E S . . . E E L 251	
calysarcin-2	266	P S F N R T P I P W S S C E P D Y N V D I C I P L D Q . . . E E E I 299	
calysarcin-1	230	R S F N R T P E G W S S E I P V I T T D D T T V P E S I E D L 264	

FIG. 13